Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 57

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 57
---
 |    131,037 |   |
| Current liabilities |     |                     |  5,378,456 |   |     |   |  5,308,003 |   |
| Working capital     |     | $                   | (5,235,105 | ) |     | $ | (5,176,966 | ) |

Working capital deficit increased by $ 58,139 from September 30, 2023 to September 30, 2024, primarily due to increase in notes payable offset by increase in accounts receivable.

| 44 |

Liquidity and Capital Resources

|                                                      |     |    Year Ended |          |   |     |      |          |   |
|:-----------------------------------------------------|:----|--------------:|---------:|:--|:----|-----:|---------:|:--|
|                                                      |     | September 30, |          |   |     |      |          |   |
|                                                      |     |          2024 |          |   |     | 2023 |          |   |
| Net cash used in operating activities                |     |             $ | (751,536 | ) |     |    $ | (173,917 | ) |
| Net cash provided by financing activities            |     |               |  631,215 |   |     |      |  243,750 |   |
| Net increase (decrease) in cash and cash equivalents |     |             $ | (120,321 | ) |     |    $ |   69,833 |   |
| Cash, beginning of year                              |     |               |  121,037 |   |     |      |   51,204 |   |
| Cash, end of year                                    |     |             $ |      716 |   |     |    $ |  121,037 |   |

Operating Activities

Net cash used in operating activities for the year ended September 30, 2024 was $751,536, compared to $173,917, for the year ended September 30, 2023, an increase of $577,619. The increase in cash used in operating activities is primarily attributable to increases in accounts receivables and prepaids. Net cash used in operating activity also includes impact of Unrealized Loss on Investment Securities of $ 204,847 and adjustment of Unearned Income.

Financing Activities

Net cash generated by financing activities for the year ended September 30